DekaBank Deutsche Girozentrale Increases Stock Position in IQVIA Holdings Inc. $IQV

DekaBank Deutsche Girozentrale boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 198,648 shares of the medical research company’s stock after acquiring an additional 7,929 shares during the period. DekaBank Deutsche Girozentrale owned about 0.12% of IQVIA worth $31,225,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Everpar Advisors LLC lifted its position in IQVIA by 4.6% in the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 62 shares during the last quarter. Private Trust Co. NA raised its holdings in shares of IQVIA by 12.5% in the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after buying an additional 67 shares during the last quarter. Ballentine Partners LLC raised its holdings in shares of IQVIA by 4.9% in the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock valued at $260,000 after buying an additional 69 shares during the last quarter. Independent Advisor Alliance raised its holdings in shares of IQVIA by 4.2% in the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock valued at $318,000 after buying an additional 72 shares during the last quarter. Finally, Nemes Rush Group LLC raised its holdings in shares of IQVIA by 15.0% in the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after buying an additional 81 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Down 0.3%

IQV stock opened at $218.04 on Thursday. The company’s 50 day simple moving average is $193.27 and its 200-day simple moving average is $170.28. The firm has a market capitalization of $37.07 billion, a PE ratio of 31.55, a P/E/G ratio of 2.40 and a beta of 1.32. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $231.34. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.64 earnings per share. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on IQV shares. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $225.00 in a report on Tuesday, September 9th. Mizuho upped their target price on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Evercore ISI upped their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Truist Financial upped their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. Finally, Redburn Partners set a $214.00 price target on shares of IQVIA in a report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.